Abstract
The antibacterial activity of zinc oxide nanoparticles (ZnO NPs) has received significant attention worldwide due to the emergence of multidrug-resistant microorganisms. Shiga toxin-producing Escherichia coli is a major foodborne pathogen that causes gastroenteritis that may be complicated by hemorrhagic colitis or hemolytic uremic syndrome. Therefore, this study aimed to evaluate the antimicrobial effect of ZnO NPs against E. coli O26 and its Shiga toxin type 2 (Stx2). Multidrug resistance phenotype was observed in E. coli O26, with co-resistance to several unrelated families of antimicrobial agents. Different concentrations of ZnO NPs nanoparticles (20 nm) were tested against different cell densities of E. coli O26 (10(8), 10(6) and 10(5) CFU/ml). The minimum inhibitory concentration (MIC) value was 1 mg/ml. Minimum bactericidal concentration (MBC) was 1.5 mg/ml, 2.5 mg/ml and 3 mg/ml, respectively, depending on ZnO NPs concentrations and bacterial cell density. Results showed a significant (P <= 0.05) decrease in Stx2 level in a response to ZnO NPs treatment. As detected by quantitative real-time PCR, ZnO NPs down-regulated the expression of the Stx2 gene (P <= 0.05). Moreover, various concentrations of ZnO NPs considerably reduced the total protein content in E. coli O26. There was a significant reduction in protein expression with increased ZnO NPs concentration compared to the non-treated control. Scanning electron micrographs (SEM) of the treated bacteria showed severe disruptive effects on E. coli O26 with increasing ZnO NPs concentration. The results revealed a strong correlation between the antibacterial effect and ZnO NPs concentrations. ZnO NPs exert their antibacterial activities through various mechanisms and could be used as a potent antibacterial agent against E. coli O26.